What is the official ID of this bill?

The official print number for this legislation is HR 5074.

When did the legislative process begin?

The process officially started on 2023-07-28.

Where can I read the full text of this legislation?

The full official text is available at: https://www.congress.gov/118/bills/hr5074/BILLS-118hr5074ih.htm

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-25.

Who is the primary sponsor?

The primary sponsor is Rep. Carter, Earl L. "Buddy" [R-GA-1].

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

What is the latest detailed status?

The latest detailed status is: Reported (Amended) by the Committee on Ways and Means. H. Rept. 118-548, Part I.

Analysis and Potential Impact of HR 5074

We don't know, that is up to you to decide. Summarizing raw data with AI is fundamentally different from predicting socio-economic outcomes. As of 2026, we believe impact assessment strictly requires a human in the loop to verify and judge. Review our public AI processing logs for full transparency, and use Lustra to track active legislation for instant status push notifications.

Extended Access to Oral Kidney Medications in Medicare

Q: What are the main provisions?

Key points include: Delays Medicare payment changes for oral kidney drugs until 2033. Kidney patients will maintain current access to oral phosphate-reducing medications. Aims to ensure treatment continuity until an intravenous alternative is available.

This bill delays the inclusion of oral-only kidney-related drugs into the Medicare payment system until 2033 or until an intravenous alternative is approved. This means kidney patients will continue to have access to current oral treatments for a longer period, potentially impacting their costs and treatment options.

Key points

Delays Medicare payment changes for oral kidney drugs until 2033.

Kidney patients will maintain current access to oral phosphate-reducing medications.

Aims to ensure treatment continuity until an intravenous alternative is available.

article Official text account_balance Process page notifications_active Track this Bill

gavel

Status:

Expired

Record your position for audit.

Why does your vote on bills matter?

It creates raw, undeniable proof. Civic Will provides the permanent data to verify the Government's loyalty towards its citizens (explained here). Start recording it now.

Additional Information

Kidney PATIENT Act of 2023

Print number: HR 5074

Sponsor: Rep. Carter, Earl L. "Buddy" [R-GA-1]

Process start date: 2023-07-28

System Note: Lustra is free, publicly auditable civic infrastructure, with full source code available on GitHub. You are reading sterilized legislative data, processed by our radical neutrality engine to strip political spin and retain factual mechanics. We process only official government data. Original documents remain the authoritative source, always verify them if you can.

Summarized by: gemini-2.5-flash-preview-05-20

Source data: api.congress.gov

AI work logs for this document launch

Extended Access to Oral Kidney Medications in Medicare

Key Questions about Extended Access to Oral Kidney Medications in Medicare